Horizon
Assessing the impact of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with established cardiovascular disease
About the study
Principal investigator
Liam Brunham
MD, PHD, FRCPC
Area(s) of medical focus
Heart
Condition(s)
Cardiopulmonary disease
Period of enrollment
2021-09-01 - 2022-06-30
Participating sites
St. Paul's Hospital
Purpose of trial
Horizon study is a pivotal phase 3 study designed to test the hypothesis that treatment with monthly subcutaneous injection of pelacarsen 80 mg will significantly reduce the risk of major adverse cardiovascular events, i.e. cardiovascular deaths, non-fatal myocardial infarction (MI), non-fatal stroke and urgent coronary revascularization in patients with established cardiovascular disease and elevated levels of Lipoprotein(a) (Lp(a)) who are treated for cardiovascular risk factors other than Lp(a) according to local practice/guidelines for the reduction of cardiovascular risk in patients with established cardiovascular disease and elevated Lp(a).
Eligibility
- Male and female 18 to ≤ 80 years of age
- Lipoprotein(a) ≥ 70 mg/dL
- In use of LDL-cholesterol lowering treatment
- Must be optimally treated for other CV risk factors (elevated blood pressure, uncontrolled diabetes) according to local practice/guidelines
- Established cardiovascular disease
Contact information
Phone Number
Co-Investigator
Dr. Gordon Francis